{"id":46228,"date":"2018-12-20T09:00:53","date_gmt":"2018-12-20T14:00:53","guid":{"rendered":"https:\/\/wfh.org\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/"},"modified":"2024-04-21T12:38:44","modified_gmt":"2024-04-21T16:38:44","slug":"la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia","status":"publish","type":"post","link":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/","title":{"rendered":"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"46228\" class=\"elementor elementor-46228 elementor-46182\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-57c8eeb elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"57c8eeb\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-036aa4a\" data-id=\"036aa4a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9f86c59 elementor-widget elementor-widget-text-editor\" data-id=\"9f86c59\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">La recomendaci\u00f3n del MASAC ofrece un panorama integral de muchos aspectos que deben tomarse en cuenta en los ensayos de terapia g\u00e9nica. Apoya los ensayos cl\u00ednicos de terapia g\u00e9nica en seres humanos, a la vez que enfatiza la importancia de identificar y mitigar los riesgos para los pacientes, de abordar los riesgos desconocidos durante el proceso del ensayo cl\u00ednico, y de la comunicaci\u00f3n abierta de todos los avances a la comunidad de hemofilia.<\/p>\r\n\r\n<p class=\"\">El <a href=\"https:\/\/wfh.org\/es\/nuestros-comites\/\" target=\"_blank\" rel=\"noopener noreferrer\">Consejo Asesor M\u00e9dico<\/a>\u00a0de la FMH apoya el \u201cDocumento del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia\u201d publicado el 6 de diciembre de 2018.<\/p>\r\n\r\n<p class=\"\">Haga clic <a href=\"https:\/\/www.hemophilia.org\/Researchers-Healthcare-Providers\/Medical-and-Scientific-Advisory-Council-MASAC\/MASAC-Recommendations\/MASAC-Document-Regarding-Risks-of-Gene-Therapy-Trials-for-Hemophilia\" target=\"_blank\" rel=\"noopener noreferrer\">aqu\u00ed<\/a>\u00a0para leer la recomendaci\u00f3n publicada por el MASAC (en ingl\u00e9s).<\/p>\r\n\r\n<p class=\"\">Si desea leer los comentarios de la FMH sobre el borrador de directrices para la industria en relaci\u00f3n con la terapia g\u00e9nica para la hemofilia (<em>Draft Guidance for Industry: Human Gene Therapy for Hemophilia<\/em>), enviados a la Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA por sus sigla en ingl\u00e9s), haga clic <a href=\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/09\/WFH-Response-to-FDA-on-gene-therapy-Dec-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">aqu\u00ed<\/a> (disponible solamente en ingl\u00e9s).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>El 6 de diciembre de 2018, el Consejo Asesor M\u00e9dico y Cient\u00edfico (MASAC por su sigla en ingl\u00e9s) de la National Hemophilia Foundation (NHF) de Estados Unidos public\u00f3 la recomendaci\u00f3n No. 254, titulada \u201cDocumento del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia\u201d.<\/p>\n","protected":false},"author":3,"featured_media":29976,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[121,196],"tags":[],"search-category":[85],"class_list":["post-46228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-declaraciones-y-notificaciones-de-la-fmh","category-noticias-medicas","search-category-article"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia | FMH - Federaci\u00f3n Mundial de Hemofilia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia\" \/>\n<meta property=\"og:description\" content=\"El 6 de diciembre de 2018, el Consejo Asesor M\u00e9dico y Cient\u00edfico (MASAC por su sigla en ingl\u00e9s) de la National Hemophilia Foundation (NHF) de Estados Unidos public\u00f3 la recomendaci\u00f3n No. 254, titulada \u201cDocumento del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia\u201d.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\" \/>\n<meta property=\"og:site_name\" content=\"FMH - Federaci\u00f3n Mundial de Hemofilia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/wfhemophilia\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-20T14:00:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-21T16:38:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1277\" \/>\n\t<meta property=\"og:image:height\" content=\"603\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Electra Rozakis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Electra Rozakis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\"},\"author\":{\"name\":\"Electra Rozakis\",\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/person\/622f4b0ed56b8e4a987dd20bef774887\"},\"headline\":\"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia\",\"datePublished\":\"2018-12-20T14:00:53+00:00\",\"dateModified\":\"2024-04-21T16:38:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\"},\"wordCount\":209,\"publisher\":{\"@id\":\"https:\/\/wfh.org\/es\/#organization\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png\",\"articleSection\":[\"Declaraciones y notificaciones de la FMH\",\"Noticias m\u00e9dicas\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\",\"url\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\",\"name\":\"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia | FMH - Federaci\u00f3n Mundial de Hemofilia\",\"isPartOf\":{\"@id\":\"https:\/\/wfh.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png\",\"datePublished\":\"2018-12-20T14:00:53+00:00\",\"dateModified\":\"2024-04-21T16:38:44+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage\",\"url\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png\",\"contentUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png\",\"width\":1277,\"height\":603,\"caption\":\"stock\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wfh.org\/es\/#website\",\"url\":\"https:\/\/wfh.org\/es\/\",\"name\":\"FMH - Federaci\u00f3n Mundial de Hemofilia\",\"description\":\"WFH - World Federation of Hemophilia\",\"publisher\":{\"@id\":\"https:\/\/wfh.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wfh.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/wfh.org\/es\/#organization\",\"name\":\"World Federation of Hemophilia\",\"url\":\"https:\/\/wfh.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg\",\"contentUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg\",\"width\":210,\"height\":63,\"caption\":\"World Federation of Hemophilia\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/wfhemophilia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/person\/622f4b0ed56b8e4a987dd20bef774887\",\"name\":\"Electra Rozakis\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia | FMH - Federaci\u00f3n Mundial de Hemofilia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/","og_locale":"es_ES","og_type":"article","og_title":"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia","og_description":"El 6 de diciembre de 2018, el Consejo Asesor M\u00e9dico y Cient\u00edfico (MASAC por su sigla en ingl\u00e9s) de la National Hemophilia Foundation (NHF) de Estados Unidos public\u00f3 la recomendaci\u00f3n No. 254, titulada \u201cDocumento del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia\u201d.","og_url":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/","og_site_name":"FMH - Federaci\u00f3n Mundial de Hemofilia","article_publisher":"https:\/\/www.facebook.com\/wfhemophilia\/","article_published_time":"2018-12-20T14:00:53+00:00","article_modified_time":"2024-04-21T16:38:44+00:00","og_image":[{"width":1277,"height":603,"url":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png","type":"image\/png"}],"author":"Electra Rozakis","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Electra Rozakis","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#article","isPartOf":{"@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/"},"author":{"name":"Electra Rozakis","@id":"https:\/\/wfh.org\/es\/#\/schema\/person\/622f4b0ed56b8e4a987dd20bef774887"},"headline":"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia","datePublished":"2018-12-20T14:00:53+00:00","dateModified":"2024-04-21T16:38:44+00:00","mainEntityOfPage":{"@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/"},"wordCount":209,"publisher":{"@id":"https:\/\/wfh.org\/es\/#organization"},"image":{"@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage"},"thumbnailUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png","articleSection":["Declaraciones y notificaciones de la FMH","Noticias m\u00e9dicas"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/","url":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/","name":"La FMH apoya la recomendaci\u00f3n del MASAC sobre los riesgos de los ensayos de terapia g\u00e9nica para la hemofilia | FMH - Federaci\u00f3n Mundial de Hemofilia","isPartOf":{"@id":"https:\/\/wfh.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage"},"image":{"@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage"},"thumbnailUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png","datePublished":"2018-12-20T14:00:53+00:00","dateModified":"2024-04-21T16:38:44+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/wfh.org\/es\/article\/la-fmh-apoya-la-recomendacion-del-masac-sobre-los-riesgos-de-los-ensayos-de-terapia-genica-para-la-hemofilia\/#primaryimage","url":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png","contentUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/04\/WFH-trilingual-logo-EN.png","width":1277,"height":603,"caption":"stock"},{"@type":"WebSite","@id":"https:\/\/wfh.org\/es\/#website","url":"https:\/\/wfh.org\/es\/","name":"FMH - Federaci\u00f3n Mundial de Hemofilia","description":"WFH - World Federation of Hemophilia","publisher":{"@id":"https:\/\/wfh.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wfh.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/wfh.org\/es\/#organization","name":"World Federation of Hemophilia","url":"https:\/\/wfh.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg","contentUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg","width":210,"height":63,"caption":"World Federation of Hemophilia"},"image":{"@id":"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/wfhemophilia\/"]},{"@type":"Person","@id":"https:\/\/wfh.org\/es\/#\/schema\/person\/622f4b0ed56b8e4a987dd20bef774887","name":"Electra Rozakis"}]}},"_links":{"self":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/posts\/46228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/comments?post=46228"}],"version-history":[{"count":0,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/posts\/46228\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/media\/29976"}],"wp:attachment":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/media?parent=46228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/categories?post=46228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/tags?post=46228"},{"taxonomy":"search-category","embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/search-category?post=46228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}